国产日本高清一区二区三区-日日搞天天日夜夜操-综合一区中综合二区中-国产视频网站在线不卡

歡迎光臨北京索萊寶科技有限公司網站!
銷售咨詢熱線:
17801761073
您的位置: 網站首頁 > 產品中心 > 抗體 > Polyclonal Antibody
  • K107319PAnti-PFDN1 Polyclonal Antibody

    Anti-PFDN1 Polyclonal Antibody 應用IHC 稀釋比例IHC 1:50-200. 交叉反應Human Mouse

    訪問次數:859    產品價格:面議    廠商性質:生產廠家    更新日期:2022-08-14

  • K107318PAnti-CCL4 Polyclonal Antibody

    Anti-CCL4 Polyclonal Antibody 應用IHC 稀釋比例IHC 1:50-200. 交叉反應Human

    訪問次數:707    產品價格:面議    廠商性質:生產廠家    更新日期:2022-08-14

  • K107317PAnti-PDCD4 Polyclonal Antibody

    Anti-PDCD4 Polyclonal Antibody 應用WB IHC 稀釋比例WB 1:5000-8000. IHC 1:50-200. 交叉反應Human

    訪問次數:702    產品價格:面議    廠商性質:生產廠家    更新日期:2022-08-14

  • K107316PAnti-ATP7A Polyclonal Antibody

    Anti-ATP7A Polyclonal Antibody 應用IHC 稀釋比例IHC 1:25-100. 交叉反應Human

    訪問次數:731    產品價格:面議    廠商性質:生產廠家    更新日期:2022-08-14

  • K107315PAnti-Caspase-6 (NT) Polyclonal Antibody

    Anti-Caspase-6 (NT) Polyclonal Antibody 應用WB IHC 稀釋比例WB 1:5000-8000. IHC 1:50-200. 交叉反應Human

    訪問次數:753    產品價格:面議    廠商性質:生產廠家    更新日期:2022-08-14

  • K107314PAnti-SCAND1 Polyclonal Antibody

    Anti-SCAND1 Polyclonal Antibody 應用WB 稀釋比例WB 1:5000-8000. 交叉反應Human

    訪問次數:723    產品價格:面議    廠商性質:生產廠家    更新日期:2022-08-14

  • K107313PAnti-LTO1 Polyclonal Antibody

    Anti-LTO1 Polyclonal Antibody 應用IHC 稀釋比例IHC 1:50-200. 交叉反應Human Mouse

    訪問次數:730    產品價格:面議    廠商性質:生產廠家    更新日期:2022-08-14

  • K107312PAnti-MED21 Polyclonal Antibody

    Anti-MED21 Polyclonal Antibody 應用IHC 稀釋比例IHC 1:50-200. 交叉反應Human Mouse Cow

    訪問次數:671    產品價格:面議    廠商性質:生產廠家    更新日期:2022-08-14

  • K107311PAnti-CD59 Polyclonal Antibody

    Anti-CD59 Polyclonal Antibody 應用IHC 稀釋比例IHC 1:50-200. 交叉反應Human

    訪問次數:691    產品價格:面議    廠商性質:生產廠家    更新日期:2022-08-14

  • K107310PAnti-RPL22 Polyclonal Antibody

    Anti-RPL22 Polyclonal Antibody 應用WB IHC 稀釋比例WB 1:5000-8000. IHC 1:50-200. 交叉反應Human

    訪問次數:662    產品價格:面議    廠商性質:生產廠家    更新日期:2022-08-14

共 1170 條記錄,當前 32 / 117 頁  首頁  上一頁  下一頁  末頁  跳轉到第頁 
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |